Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The STELLAR trial: a phase II/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma.
Janssen JBE, Brahm CG, Driessen CML, Nuver J, Labots M, Kouwenhoven MCM, Sanchez Aliaga E, Enting RH, de Groot JC, Walenkamp AME, van Linde ME, Verheul HMW. Janssen JBE, et al. Among authors: labots m. Brain Commun. 2024 Jul 30;6(4):fcae241. doi: 10.1093/braincomms/fcae241. eCollection 2024. Brain Commun. 2024. PMID: 39114330 Free PMC article. Clinical Trial.
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma.
van Duin IAJ, Schuiveling M, Ter Maat LS, Veta M, van Eijs MJM, Verheijden RJ, van den Berkmortel FWPJ, Boers-Sonderen MJ, Hospers GAP, Labots M, de Groot JWB, Kapiteijn E, Piersma D, Vreugdenhil G, Westgeest H, Schrader AMR, van Diest PJ, Blokx WAM, Suijkerbuijk KPM. van Duin IAJ, et al. Among authors: labots m. Immunooncol Technol. 2024 Jun 12;24:100714. doi: 10.1016/j.iotech.2024.100714. eCollection 2024 Dec. Immunooncol Technol. 2024. PMID: 39045171 Free PMC article.
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.
Zeverijn LJ, Geurts BS, Battaglia TW, van Berge Henegouwen JM, de Wit GF, Hoes LR, van der Wijngaart H, van der Noort V, Roepman P, de Leng WWJ, Jansen AML, Chalabi M, van Herpen CML, Devriese LA, Erdkamp FLG, Labots M, de Jonge MJA, Kerver ED, Bins AD, Leek LVM, Notohardjo JCL, van den Eertwegh AJM, Wessels LFA, Verheul HMW, Gelderblom H, van de Haar J, Voest EE. Zeverijn LJ, et al. Among authors: labots m. Clin Cancer Res. 2024 Oct 1;30(19):4339-4351. doi: 10.1158/1078-0432.CCR-24-0480. Clin Cancer Res. 2024. PMID: 39024037
Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma.
van Duin IAJ, Schuiveling M, Ter Maat LS, van Amsterdam WAC, van den Berkmortel F, Boers-Sonderen M, de Groot JWB, Hospers GAP, Kapiteijn E, Labots M, Piersma D, Schrader AMR, Vreugdenhil G, Westgeest H, Veta M, Blokx WAM, van Diest PJ, Suijkerbuijk KPM. van Duin IAJ, et al. Among authors: labots m. Eur J Cancer. 2024 Sep;208:114190. doi: 10.1016/j.ejca.2024.114190. Epub 2024 Jun 30. Eur J Cancer. 2024. PMID: 38991284 Free article.
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma.
Verheijden RJ, Burgers FH, Janssen JC, Putker AE, Veenstra SPGR, Hospers GAP, Aarts MJB, Hehenkamp KW, Doornebosch VLE, Verhaert M, van den Berkmortel FWPJ, Chatzidionysiou K, Llobell A, Barros M, Maria ATJ, Takeji A, García Morillo JS, Lidar M, van Eijs MJM, Blank CU, Aspeslagh S, Piersma D, Kapiteijn E, Labots M, Boers-Sonderen MJ, van der Veldt AAM, Haanen JBAG, May AM, Suijkerbuijk KPM. Verheijden RJ, et al. Among authors: labots m. Eur J Cancer. 2024 Aug;207:114172. doi: 10.1016/j.ejca.2024.114172. Epub 2024 Jun 15. Eur J Cancer. 2024. PMID: 38905818 Free article.
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM, Notohardjo JCL, de Joode K, Velker EL, Haanen JBAG, Suijkerbuijk KPM, Aarts MJB, de Groot JWB, Kapiteijn E, van den Berkmortel FWPJ, Westgeest HM, de Gruijl TD, Retel VP, Cuppen E, van der Veldt AAM, Labots M, Voest EE, van de Haar J, van den Eertwegh AJM. Leek LVM, et al. Among authors: labots m. Sci Rep. 2024 May 16;14(1):11244. doi: 10.1038/s41598-024-61150-y. Sci Rep. 2024. PMID: 38755213 Free PMC article.
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy.
Geurts BS, Zeverijn LJ, van Berge Henegouwen JM, van der Wijngaart H, Hoes LR, de Wit GF, Spiekman IA, Battaglia TW, van Beek DM, Roepman P, Jansen AM, de Leng WW, Broeks A, Labots M, van Herpen CM, Gelderblom H, Verheul HM, Snaebjornsson P, Voest EE. Geurts BS, et al. Among authors: labots m. J Pathol. 2024 Jul;263(3):288-299. doi: 10.1002/path.6279. Epub 2024 May 15. J Pathol. 2024. PMID: 38747304
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.
Verkerk K, Geurts BS, Zeverijn LJ, van der Noort V, Verheul HMW, Haanen JBAG, van der Veldt AAM, Eskens FALM, Aarts MJB, van Herpen CML, Jalving M, Gietema JA, Devriese LA, Labots M, Barjesteh van Waalwijk van Doorn-Khosrovani S, Smit EF, Bloemendal HJ. Verkerk K, et al. Among authors: labots m. Lancet Reg Health Eur. 2024 Mar 5;39:100875. doi: 10.1016/j.lanepe.2024.100875. eCollection 2024 Apr. Lancet Reg Health Eur. 2024. PMID: 38464480 Free PMC article.
Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics.
van der Wijngaart H, Beekhof R, Knol JC, Henneman AA, de Goeij-de Haas R, Piersma SR, Pham TV, Jimenez CR, Verheul HMW, Labots M. van der Wijngaart H, et al. Among authors: labots m. Clin Proteomics. 2023 Nov 8;20(1):49. doi: 10.1186/s12014-023-09437-6. Clin Proteomics. 2023. PMID: 37940875 Free PMC article.
63 results